军团菌检测试剂盒（免疫捕获法）

广州健仑生物科技有限公司

主要用途：用于检测尿样中嗜肺军团菌血清型1抗原，以支持军团菌感染的诊断。

产品规格：20T/盒

存储条件：2-30℃

军团菌检测试剂盒（免疫捕获法）

我司还提供其它进口或国产试剂盒：登革热、疟疾、西尼罗河、立克次体、无形体、蜱虫、恙虫、利什曼原虫、RK39、汉坦病毒、深林脑炎、流感、A链球菌、合胞病毒、腮病毒、乙脑、寨卡、黄热病、基孔肯雅热、克锥虫病、违禁品滥用、肺炎球菌、军团菌、化妆品检测、食品安全检测等试剂盒以及日本生研细菌分型诊断血清、德国SiFin诊断血清、丹麦SSI诊断血清等产品。

欢迎咨询

欢迎咨询2042552662

【产品介绍】

二维码扫一扫

【公司名称】 广州健仑生物科技有限公司
【】    杨永汉 
【】 
【腾讯 】 2042552662
【公司地址】 广州清华科技园创新基地番禺石楼镇创启路63号二期2幢101-3室
【企业文化】

经过反复试验，研究人员zui终发现了这第二个基因，即存在于大脑中的特殊tRNAs中的GTPBP2——tRNAs的作用是帮助DNA翻译成蛋白。这种tRNA基因的突变会引起核糖体停止在一个特殊的DNA序列上，减慢蛋白合成过程。
研究人员指出，由于这项研究采用的遗传背景是用于构建其他人类疾病模型，因此采用这种小鼠模型的研究人员也要多加注意。
杜克大学医学院的科学家在HIV感染的人中发现，产生广谱中和抗体的一种免疫机制。这项研究结果在很大程度上是HIV疫苗诱导产生有效的中和抗体的关键。相关文章发表于2014年7月24日的《Cell》杂志上。该研究小组发现，两种不同的B细胞谱系抗体联手，刺激备受追捧的广谱中和抗体对抗HIV。该研究组由杜克大学艾滋病毒/艾滋病疫苗免疫学，免疫原发现(CHAVI-ID)中心杜克大学人类疫苗研究所的主任巴顿·海恩斯，以及该疫苗研究中心的国家过敏和传染病研究所(NIAID)的主任John Mascola医学博士所的。
海恩斯说，这些可中和多种hiv病毒株的抗体的激活是是一个性疫苗的关键策略。高水平的这种抗体在约20%的艾滋病毒感染者中产生。
去年，该研究组在Nature杂志上*描述广谱中和抗体(bnAbs)的共同进化，以及病毒激活感染者内的这些抗体。现在，同样的研究小组报告了患者体内的免疫系统的B细胞学会中和许多种HIV病毒株的确切机制。
在这项新研究中，科学家惊讶地发现，一个辅助的中和抗体组和交叉反应中和抗体合作，产生一套强而有力的广谱中和抗体。其他辅助谱系包含与导致感染的病毒中和的抗体。

这种抗体靶向病毒的外膜区域，该区域也能够与广谱中和抗体结合。在这样做时，辅助谱系抗体选择具有较强能力的病毒刺激广谱中和抗体系。
因此，一组抗体选择一组病毒逃逸突变体“教导”广谱中和抗体系如何中和HIV变种。科学家推测，这个过程会反复发生在整个感染中，导致中和多种HIV毒株的抗体谱的产生。
“一个bnAb谱系的成熟可以通过辅助谱系来提升的这一发现，对艾滋病疫苗的发展有着重要的影响，”文章*作者、杜克大学人类疫苗研究所Feng Gao博士说。“来自于初始传播/原始病毒的免疫原的反复免疫，以及逃避变体与bnAb谱系具有更高的结合能力，都可能需要激活bnAbs。”
“下一步是要在能够产生广谱中和抗体的其他个体中进行类似的研究，并确定诱导这种抗体的其他特异性是一个普遍的机制，” 海恩斯说。“然后，zui终证明，这一发现可用于设计可诱导广谱中和抗体的免疫原。”
利用这项研究的结果，该研究模仿自然感染艾滋病毒的光谱中和抗体发展，已经设计出一种疫苗免疫原，有选择性地触发产生抗体的B细胞进行合作，产生广谱中和抗体。
随着癌症的发育，正常的血液供给慢慢不能满足其需求，因此过度生长的肿瘤组织吸收的氧气量就会比正常组织少，这种低氧环境称之为缺氧状态，缺氧状态往往和不同类型的恶性肿瘤的发生相关。
这项研究中研究人员利用结肠癌组织进行研究发现，缺氧条件可以诱发关键的肿瘤抑制基因MLH1发生沉默;与此同时研究人员也发现了一种名为LSD1的酶类，这种酶是一种赖氨酸特殊的脱甲基酶，酶类LSD1连同MLH1都可以作为逆转或者阻断沉默过程的靶点;由于LSD1是一种特殊酶类，因此科学家们可以利用小分子对其产生的靶向作用来抑制其活性。

After trial and error, the researchers finally discovered the second gene, the role of GTPBP2 - tRNAs in specific tRNAs found in the brain, to help translate DNA into proteins. This tRNA gene mutation causes the ribosome to stop on a particular DNA sequence, slowing the protein synthesis process.
Researchers noted that as the genetic background used in this study was to build other human disease models, researchers using this mouse model should pay more attention.
Scientists at Duke University School of Medicine found in HIV-infected humans an immune mechanism that produces broad-spectrum neutralizing antibodies. The results of this study are to a large extent the key to the generation of effective neutralizing antibodies by HIV vaccines. The article appeared in the July 24, 2014 "Cell" magazine. The team found that two different B-cell lineage antibodies work in tandem to stimulate the highly sought-after broad-spectrum neutralizing antibodies against HIV. The research team was led by Barton Haynes, director of the Duke University HIV Vaccine Immunology, Duke University Center for Human Immunization Discovery (CHAVI-ID) Center at Duke University, and the National Allergy and Infectious Diseases Led by John Mascola, MD, director of the Institute (NIAID).
Haynes said the activation of antibodies that neutralize multiple hiv strains is a key strategy for a global vaccine. High levels of this antibody are produced in about 20% of HIV-infected individuals.
Last year, the team first described in Nature the co-evolution of broad-spectrum neutralizing antibodies (bnAbs), and the virus activates these antibodies in infected individuals. The same team now reports on the exact mechanism by which B cells in the immune system in a patient learn to neutralize many of the HIV strains.
In this new study, scientists were surprised to find that a co-neutralizing antibody group works with cross-reacting neutralizing antibodies to produce a robust set of broad-spectrum neutralizing antibodies. Other accessory lineages contain antibodies that neutralize the virus that causes the infection.

This antibody targets the outer membrane region of the virus, which is also capable of binding to a broad spectrum of neutralizing antibodies. In doing so, the accessory lineage antibody selects a more competent virus to stimulate the broad-spectrum neutralizing antibody system.
Thus, a panel of antibodies selected from a group of virus escape mutants "teaches" how broad-spectrum neutralizing antigens neutralize HIV variants. Scientists speculate that this process occurs repeatedly throughout the infection, resulting in the production of antibody profiles that neutralize multiple HIV strains.
"The discovery that the maturation of a bnAb lineage can be enhanced by ancillary lineages has a significant impact on the development of an AIDS vaccine," said lead author Feng Gao, PhD, of Duke University's Human Vaccine Institute. "Repeated immunizations from immunogens that originate / originate the virus, and the ability of escape variants to bind to the bnAb lineage, may require the activation of bnAbs."
"The next step is to do similar research in other individuals that are capable of producing broad-spectrum neutralizing antibodies and to establish that other specificities that induce such antibodies are a common mechanism," Haines said. "And then it turns out that this finding can be used to design immunogens that induce broad-spectrum neutralizing antibodies."
Using the results of this study, which mimicked the development of neutralizing antibodies in naturally infected HIV, a vaccine immunogen has been designed that selectively triggers the production of antibody-producing B cells to produce broad-spectrum neutralizing antibodies.
With the development of cancer, the normal blood supply slowly can not meet their needs, so excessive growth of tumor tissue to absorb oxygen than the normal tissue less, this hypoxic environment called hypoxia, hypoxia often And different types of malignancies related to the occurrence.
In this study, researchers using colon cancer tissue research found that hypoxia can induce key tumor suppressor gene MLH1 silence; at the same time researchers also found a class called LSD1 enzymes, this enzyme is a Species of lysine-specific demethylase, enzymes LSD1 together with MLH1 can be used as reversing or blocking the process of silencing the target; because LSD1 is a special enzyme, so scientists can make use of small molecules on their target To act to inhibit its activity.